California Privacy Notice
Effective September 30, 2026
This California Privacy Notice supplements the PlexusDx Privacy Policy for California residents.
Categories of information
Depending on your relationship with PlexusDx, we may collect identifiers and contact information; account and transaction information; internet or electronic activity; geolocation information at an appropriate level when provided or permitted; professional or demographic information when relevant; health-related and other sensitive information; customer-support communications; and inferences derived from information we collect.
Purposes and disclosures
We use personal information to operate and secure PlexusDx; provide requested services; facilitate independent clinical care and pharmacy fulfillment; administer accounts, billing, and communications; prevent fraud; comply with law; improve services; and perform analytics and marketing where legally permitted. We may disclose information to independent healthcare providers, pharmacies, technology and service providers, payment processors, shipping providers, professional advisers, and government authorities where appropriate.
Sale, sharing, and targeted advertising
PlexusDx does not sell personal information for money. Certain advertising and analytics activities on public marketing pages may be considered sale or sharing under California law. Eligible users can exercise applicable opt-out rights through PlexusDx's Your Privacy Choices mechanism. PlexusDx honors Global Privacy Control where required.
Advertising technologies are excluded from clinical intake and authenticated patient areas. PlexusDx does not send medical intake responses, diagnoses, prescriptions, medication details, allergies, side effects, or provider communications to advertising platforms for targeted advertising.
Sensitive personal information
PlexusDx uses sensitive personal information for purposes reasonably necessary to provide requested services, facilitate care and fulfillment, maintain security, comply with law, and other purposes permitted by California law. PlexusDx does not use sensitive clinical information to infer characteristics for unrelated targeted advertising.
California rights
Subject to applicable exceptions, California residents may have rights to know or access personal information, correct inaccurate information, request deletion, obtain information about categories of collection and disclosure, and opt out of sale or sharing. PlexusDx will not unlawfully discriminate against you for exercising privacy rights.
Requests may be submitted to support@plexusdx.com. We may verify identity based on the nature and sensitivity of the request. Authorized agents may submit requests subject to appropriate authorization and verification.
Contact
PlexusDx, Inc.
6110 McFarland Station Drive, #604
Alpharetta, GA 30004
support@plexusdx.com
Important information
Compounded medications are not approved by the FDA or reviewed for quality, safety, or efficacy.
Novo Nordisk, Inc. is the only United States company with FDA-approved products containing semaglutide, identified under the trade names Rybelsus®, Ozempic®, and Wegovy®.
Lilly USA LLC is the only United States company with FDA-approved products containing tirzepatide, identified under the trade names Zepbound® and Mounjaro®.
The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.
